doi: 10.1161/CIRCULATIONAHA.113.005081 34 CastanedaAMDutra-RufatoAJuarezMJGrosembacherLGonzalez-TorresHMussoCG
Our popular weight loss and diabetes services Sources: PlushCare is dedicated to providing you with accurate and trustworthy health information
Wegovy (Semaglutide Injection): This once-weekly injectable remains a leading choice for GLP-1 weight loss, with clinical trials showing an average body weight reduction of 14.9%
The goal should be improved metabolic function, better body composition, and a lower-risk physiologic state
However, this litigation is much earlier in the process than those involving stomach paralysis
Current FDA-approved uses for semaglutide include : Type 2 diabetes management (glycemic control) Cardiovascular risk reduction in type 2 diabetes with established CVD (Ozempic) Cardiovascular risk reduction in adults with established CVD and obesity/overweight (Wegovy) Chronic weight management in obesity or overweight with comorbidities Clinicians should prescribe semaglutide according to FDA-approved indications and established clinical guidelines, including those from the American Diabetes Association (ADA) and American College of Physicians (ACP)
